AbbVie, a global biopharmaceutical leader, has reported disappointing results from a phase 2 clinical trial evaluating its interleukin-1 (IL-1) targeting drug, ABBV-668, as a monotherapy for patients with moderate to…
A new Missouri law is shining a spotlight on the vital need for awareness of rare childhood diseases, thanks in large part to the advocacy efforts of a Eureka, Missouri…
Acknowledgement: This poem, originally written by Olivia Thompson, was provided to Patient Worthy by our friends at Elephants & Tea. To see the original, please click here. One welcomes a…
© Copyright 2024 Patient Worthy
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
